Presbyopia

Latest News

Visus Therapeutics completes enrollment in BRIO-I Phase 3 clinical trial of Brimochol PF for the treatment of presbyopia
Visus Therapeutics completes enrollment in BRIO-I Phase 3 clinical trial of Brimochol PF for the treatment of presbyopia

March 22nd 2023

BRIO-I is a double-masked, randomized, multi-center, safety and efficacy study that enrolled emmetropic phakic and pseudophakic presbyopic subjects.

FDA accepts Orasis Pharmaceuticals' NDA for CSF-1 for treatment of presbyopia
FDA accepts Orasis Pharmaceuticals' NDA for CSF-1 for treatment of presbyopia

February 21st 2023

Florida State University teaming up with ophthalmology drug developer
Florida State University teaming up with ophthalmology drug developer

February 9th 2023

Ocuphire Pharma enrolls first patient in VEGA-2 phase 3 trial for presbyopia treatment
Ocuphire Pharma enrolls first patient in VEGA-2 phase 3 trial for presbyopia treatment

January 9th 2023

VEGA-1 Trial: Focusing on presbyopia
VEGA-1 Trial: Focusing on presbyopia

December 31st 2022

Video Interviews

More News

© 2023 MJH Life Sciences

All rights reserved.